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Most patients with low-grade non-Hodgkin’s lymphoma 
(NHL) present with disseminated disease, although many 
are asymptomatic at diagnosis. Several initial approaches 
have been used to treat such patients, but none of the treat-
ment options have resulted in long-term disease-free surviv-
al in majority of these patients. Although some patients 
may achieve complete remission (CR), the remission is 
short-lived and usually followed by a relapse. Therefore, 
the prognosis for patients with indolent lymphoma (median 
survival, 8-10 years) has not improved much over time 
[1]. However, recent survival data for patients with advanced 
indolent lymphoma suggest that the overall survival (OS) 
rate has improved over the last 25 years, probably because 
of sequential application of different chemotherapy regi-
mens, use of biologic agents, and improved supportive care.
Conventional therapy for low-grade NHL involves mono-
therapy with an alkylating agent (chlorambucil or cyclo-
phosphamide) or administration of alkylating agents in com-
bination with or without anthracyclines (cyclophospha-
mide, vincristine, and prednisone or cyclophosphamide, 
vincristine, prednisone, and doxorubicin), depending on the 
clinical aggressiveness of the disease. The unsatisfactory re-
sults observed in terms of CR and long-term disease control 
led to the therapeutic investigation of purine analogues in 
this disease subset.
The past decade has witnessed the emergence of fludar-
abine as an active agent for low-grade NHL treatment. 
Although early trials with single-agent fludarabine showed 
response rates of 30-50% in previously treated patients, 
recent efforts have focused on combining fludarabine with 
other agents, especially mitoxantrone [2, 3] and cyclo-
phosphamide [4]. Clinical trials with these combination regi-
mens have reproducibly yielded overall response rates of 
60-90% [5].
The use of fludarabine, mitoxantrone, and dexamethasone 
(FND) induced a response rate of 94%, with a CR rate 
of 46% (duration of CR [median], 21 months). Although 
FND was well tolerated, many patients developed myelosup-
pression and opportunistic infections including Pneumocys-
tis carinii, herpes zoster, and mycobacterial infections. The 
potent antilymphocytic activity of fludarabine, particularly 
for T cells, has been incriminated for this effect. Similar 
toxicities were reported in chronic lymphocytic leukemia 
(CLL) patients treated with fludarabine: addition of cortico-
steroids increased opportunistic infections without inducing 
significant antitumor effects.
The fludarabine and cyclophosphamide (FC) combination 
has been extensively studied for the management of CLL 
patients. FC was used as the first-line treatment and was 
associated with high rates of objective response (86-100%) 
and CR (20-60%). These results have been recently con-
firmed by 3 phase III studies, in which FC was compared 
with fludarabine and chlorambucil. The major toxicity in 
these studies was hematological: grade IV neutropenia asso-
ciated with severe drug-related lymphopenia caused a sub-
stantial rate of infectious complications. The most important 
complication after myelosuppression was early appearance 
of second tumors at the follow-up. Therapy-related myelo-
dysplasia (tMDS) and therapy-related acute myeloid leuke-
mia (tAML) are well-known complications of combination Korean J Hematol 2011;46:145-7.
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regimens of fludarabine and alkylating agents. Nearly 10% 
of lymphoma patients treated with standard chemotherapy 
develop tMDS/tAML. FC regimen may increase the risk 
of tMDS/tAML probably because of their synergistic effects 
of induction and inhibition of DNA repair following DNA 
damage [6].
Recently, immunochemotherapy with rituximab (chi-
meric anti-CD20 monoclonal antibody) has shown im-
pressive response rates and prolonged progression-free sur-
vival in patients with indolent lymphomas [7]. There are 
2 possible explanations for the survival advantage with ritux-
imab-chemotherapy (R-chemo): patients treated with R- 
chemo may have higher initial response rates and/or pro-
longed disease control than that shown by patients treated 
with chemotherapy alone. The efficacy of rituximab as a 
single-agent therapy was originally established in a pivotal 
study performed in 166 patients with refractory or relapsed 
indolent B-cell NHL; the overall response rate was 48%. 
Early preclinical data suggested rituximab augments the sen-
sitivity of tumor cells to cytotoxic drugs. R-chemo anti-
lymphoma activity reflects different modes of action and 
the ability of the antibody to modify molecular signaling 
pathways. The latter is associated with decreased expression 
of antiapoptotic gene products (bcl-2 and bcl-xL) and sensiti-
zation of drug-resistant B-cell NHL cells to chemotherapy. 
However, there is no clarity on the contribution of these 
mechanisms to the cytotoxicity of rituximab and in vivo 
relevance of these pathways in follicular or mantle cell 
lymphoma patients. The impact of rituximab maintenance 
treatment in OS is one of the most important aspects for 
patients with indolent NHL. Randomized trials carried out 
by GLSG (German Low Grade Lymphoma Study Group) 
and EORTC (European Organization for Research and 
Treatment of Cancer) have shown that rituximab main-
tenance therapy after immunochemotherapy [8, 9] and after 
chemotherapy [8] leads to better outcomes than those ach-
ieved after post-therapy monitoring alone. The difference 
in OS between patients treated initially with immunoche-
motherapy or chemotherapy alone followed by rituximab 
maintenance therapy, might be minor in current and future 
practice.
Some new data is available on bortezomib and bendamus-
tine combination therapy for follicular lymphoma. Protea-
some inhibitors such as bortezomib have broad-spectrum 
activity against cancer cells, including inhibition and modu-
lation of nuclear factor κB activity, and modification of 
cell-cycle and pro- and antiapoptotic pathways. In multiple 
phase II studies, bortezomib showed variable activity when 
used as a single-agent against follicular lymphoma. The over-
all response rate was 16-41%, with few CRs. Bortezomib 
may potentiate the cytotoxicity of other chemotherapy 
drugs. These findings have prompted further investigation 
of different chemotherapy regimens combining bortezomib 
with rituximab in follicular lymphoma patients [10].
Although this article describes an important study of flu-
darabine-containing regimen for Korean patients with in-
dolent lymphoma, this study has some limitations because 
of insurance. A variety of chemotherapy regimens (FND, 
FC, and FC with rituximab) were administered in the cases 
included in this analysis. On the basis of the currently avail-
able data, I cannot comment on the best first-line chemo-
therapy regimen or the optimal number of chemotherapy 
cycles needed to treat patients with indolent lymphoma.
Further prospective randomized trials are required to de-
termine the best first-line chemotherapy regimen for in-
dolent lymphoma patients, and separate and adequately 
powered trials are needed for untreated patients and patients 
with relapsed or refractory indolent lymphoma. New combi-
nation regimens, such as bortezomib, bendamustine, and 
rituximab, should be evaluated in cases of other histological 
subtypes of indolent lymphomas.
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